bn-80933 has been researched along with Brain-Injuries* in 2 studies
1 review(s) available for bn-80933 and Brain-Injuries
Article | Year |
---|---|
Nitric oxide synthases: targets for therapeutic strategies in neurological diseases.
Glutamate excitotoxicity, oxidative stress, and mitochondrial dysfunctions are common features leading to neuronal death in cerebral ischemia, traumatic brain injury, Parkinson's disease, Huntington's disease, Alzheimer's disease and amyotrophic lateral sclerosis. Nitric oxide (NO) alone or in cooperation with superoxide anion and peroxynitrite is emerging as a predominant effector of neurodegeneration The use of NO synthase (NOS) inhibitors and mutant mice lacking each NOS isoform have provided evidence for the injurious effects of NO derived from neuronal or inducible isoforms. New neuroprotective strategies have been proposed with selective NOS inhibitors for the neuronal (ARL17477) or the inducible (1400 W) isoforms or with compounds combining in one molecule selective nNOS inhibition and antioxidant properties (BN 80933), in experimental ischemia-induced acute neuronal damage. The efficacy of these new strategies is well established in acute neuronal injury but remains to be determined in more chronic neurological diseases. Topics: Alzheimer Disease; Amidines; Amyotrophic Lateral Sclerosis; Animals; Benzylamines; Brain Injuries; Brain Ischemia; Enzyme Induction; Humans; Huntington Disease; Mice; Mice, Neurologic Mutants; Mice, Transgenic; Nerve Degeneration; Nerve Tissue Proteins; Nervous System Diseases; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Organ Specificity; Polymethacrylic Acids; Pyrazines; Thiophenes | 1999 |
1 other study(ies) available for bn-80933 and Brain-Injuries
Article | Year |
---|---|
BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: a promising neuroprotective strategy.
Nitric oxide (NO) and reactive oxygen species (ROS) act independently as well as cooperatively to induce neuronal death in acute neurological disorders. Inhibition of neuronal nitric oxide synthase (nNOS) and inhibition of lipid peroxidation induced by ROS have both been proposed as neuroprotective strategies in stroke and trauma. Recently, in our laboratory, the combination of the two strategies was found to be synergistic in reducing neuronal damage. Here, we report that BN 80933 [(S)-N-[4-[4-[(3,4-dihydro-6-hydroxy-2, 5,7, 8-tetramethyl-2H-1-benzopyran-2-yl)carbonyl]-1-piperazinyl]phenyl]-2- thiophenecarboximidamide], a compound that combines potent antioxidant and selective nNOS inhibitory properties in vitro, affords remarkable neuronal protection in vivo. Intravenous administration of BN 80933 significantly reduced brain damage induced by head trauma in mice, global ischemia in gerbils, and transient focal ischemia in rats. Treatment with BN 80933 (0.3-10 mg/kg) significantly reduced infarct volume (>60% protection) and enhanced behavioral recovery in rats subjected to transient (2-h) middle cerebral artery occlusion and 48-h or 7-day reperfusion. Furthermore, treatment with BN 80933 commencing up to 8 h after the onset of ischemia resulted in a significant improvement of neurological outcome. All these results indicate that BN 80933 represents a class of potentially useful therapeutic agents for the treatment of stroke or trauma and possibly neurodegenerative disorders that involve both NO and ROS. Topics: Animals; Aorta; Brain Injuries; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gerbillinae; Inhibitory Concentration 50; Kinetics; Lipid Peroxidation; Male; Mice; Myocardial Ischemia; Neurons; Neuroprotective Agents; Nitric Oxide Synthase; Organ Culture Techniques; Pyrazines; Rats; Rats, Sprague-Dawley; Thiophenes; Time Factors | 1999 |